Fundraising Fox

Elgia Therapeutics

San Diego, US · Founded 2019 · Delaware corporation

Elgia Therapeutics is a biopharmaceutical company developing novel molecular therapies for metabolic, inflammatory, and fibrotic diseases. Its work draws on expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.

BiotechHealthtech

Founders & leadership

Elgia Therapeutics was founded in 2019 by Michael Karin, Michelle Arkin, and Adam Renslo.

MK
Michael Karin
MA
Michelle Arkin
AR
Adam Renslo
BH
Brian HubbardNamed on SEC filing
AS
Alan SaltielNamed on SEC filing
TC
Thomas CollNamed on SEC filing
AF
Ariel FeldsteinNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$2.3M disclosed across 1 round · 2020

▶$2.3MraisedMay 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian HubbardDirector
  • Alan SaltielExecutive Officer, Director
  • Thomas CollExecutive Officer
  • Ariel FeldsteinExecutive Officer, Director
Offering amount
$10M
Amount sold
$2.3M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Areteia Therapeutics11 shared keywordsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
Coya Therapeutics10 shared keywords
AltaThera Pharmaceuticals9 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
Lycia Therapeutics6 shared keywordsLycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.
Antheia, Inc.6 shared keywordsAntheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

Companies competing with Elgia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2023$180.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Elgia Therapeutics do?
Elgia Therapeutics is a biopharmaceutical company developing novel molecular therapies for metabolic, inflammatory, and fibrotic diseases. Its work draws on expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.
Who founded Elgia Therapeutics?
Elgia Therapeutics was founded by Michael Karin, Michelle Arkin, Adam Renslo in 2019.
How much funding has Elgia Therapeutics raised?
Elgia Therapeutics has disclosed $2.3M raised across 1 round.
Where is Elgia Therapeutics headquartered?
Elgia Therapeutics is headquartered in San Diego, US.